Head and neck squamous cell carcinoma (HNSCC) accounts for 300,000 deaths per year worldwide, and overall survival rates have shown little improvement over the past three decades. Current treatment methods including surgery, chemotherapy, and radiotherapy leave patients with secondary morbidities. Thus, treatment of HNSCC may benefit from exploration of natural compounds as chemopreventive agents. With excellent safety profiles, reduced toxicities, antioxidant properties, and general acceptance for use as dietary supplements, natural compounds are viewed as a desirable area of investigation for chemoprevention. Though most of the field is early in development, numerous studies display the potential utility of natural compounds against HNSCC. These compounds face additional challenges such as low bioavailability for systemic delivery, potential toxicities when consumed in pharmacologic doses, and acquired resistance. However, novel delivery vehicles and synthetic analogues have shown to overcome some of these challenges. This review covers 11 promising natural compounds in the chemoprevention of HNSCC including vitamin A, curcumin, isothiocyanate, green tea, luteolin, resveratrol, genistein, lycopene, bitter melon, withaferin A, and guggulsterone. The review discusses the therapeutic potential and associated challenges of these agents in the chemopreventive efforts against HNSCC. Cancer Prev Res; 11(8); 441–50. ©2018 AACR.

Head and neck squamous cell carcinoma (HNSCC) is the sixth most common cancer in the United States and accounts for more than 300,000 deaths per year worldwide (1). Despite numerous therapies, HNSCC is associated with poor overall survival rates (<50%) that have not improved significantly within the last 30 years.

Exposure to tobacco, alcohol, and numerous other environmental factors can result in field cancerization (1). More recently, HNSCC has been linked to human papilloma virus (HPV) infection. Cessation of exposure to carcinogens is an effective way to decrease incidence of HNSCC. However, this is not always an effective means of prevention as genetic alterations caused by initial carcinogen exposures can ultimately lead to transformation long after cessation (1). Standard therapeutic approaches such as surgical intervention, radiotherapy, and chemotherapy are effective in a limited subgroup of patients and often result in additional morbidities. Therefore, there is a great need for prevention and early diagnosis of high-risk premalignant lesions (2). Chemoprevention is defined as the use of natural or synthetic substances to reverse, suppress, or prevent the initiation, promotion, or progression of cancer (2).

Use of natural compounds for chemoprevention is highly compelling due to their safety, low toxicity, and general acceptance as dietary supplements (3). These natural dietary agents hold great promise for chemopreventive use due to their ability to decrease the occurrence of cancer (3). However, there are many associated challenges with the use of natural compounds. Some have increased toxicities or low bioavailability and may trigger resistance mechanisms, all of which are accentuated by using these compounds in pharmacologic doses (2). For chemoprevention to be feasible in premalignant populations, the compound must be well-tolerated and have long-lasting benefit. Moreover, the various signaling pathways contributing to HNSCC tumorigenesis mandate use of compounds with multiple molecular targets (2).

Several approaches including development of synthetic analogues, adding bioadjuvant compounds to conventional therapies, using nanoparticles and other delivery agents to improve bioavailability, and increasing solubility using phospholipid complexes show promise in overcoming these challenges (4–6). In this review, we highlight natural compounds with the most potential as chemoprevention agents against HNSCC (Fig. 1).

Figure 1.

The schematic represents various signaling pathways that occur within tumor cells, which allow for cell growth, proliferation, and invasion. The arrows between the signaling molecules represent progressions in the pathway. For example, IGFR signals through the JAK/STAT3 pathway to allow for cell proliferation. The natural compounds discussed can promote cell apoptosis (Luteolin, Resveratrol) and/or inhibit cell growth, proliferation, and invasion (Luteolin, Resveratrol, Genistein, GTE, Curcumin, ITCs, Lycopene). Abbreviations: CDK4/6, cyclin-dependent kinase 4/6; E2F, transcription factor coder for eukaryotes; p53, tumor protein p53; p21, cyclin-dependent kinase inhibitor 1; Rb, retinoblastoma protein; JAK1, Janus kinase 1; STAT3, signal transducer and activator of transcription 3.

Figure 1.

The schematic represents various signaling pathways that occur within tumor cells, which allow for cell growth, proliferation, and invasion. The arrows between the signaling molecules represent progressions in the pathway. For example, IGFR signals through the JAK/STAT3 pathway to allow for cell proliferation. The natural compounds discussed can promote cell apoptosis (Luteolin, Resveratrol) and/or inhibit cell growth, proliferation, and invasion (Luteolin, Resveratrol, Genistein, GTE, Curcumin, ITCs, Lycopene). Abbreviations: CDK4/6, cyclin-dependent kinase 4/6; E2F, transcription factor coder for eukaryotes; p53, tumor protein p53; p21, cyclin-dependent kinase inhibitor 1; Rb, retinoblastoma protein; JAK1, Janus kinase 1; STAT3, signal transducer and activator of transcription 3.

Close modal

Vitamin A is a fat-soluble vitamin that is the first and best studied natural chemopreventive compound tested in HNSCC. Analogues of vitamin A, such as retinoids or carotenoids, can be found in liver, fish oil, milk, eggs, and various fruits and vegetables. Several clinical studies have looked at the effect of various vitamin A derivatives on oral premalignancies, second primary tumors (SPT), and survival rates (Table 1).

Table 1.

Important natural forms and derivatives of chemopreventive natural compounds in HNSCC

Important natural forms and derivatives
Natural compoundNameSource
Vitamin A Retinyl palmitate, isotretinoin, β-carotene (6–9, 12, 13, 98) 
Isothiocyanate PEITC, BITC, sulforaphane (28, 31, 36) 
Green tea EC, EGC, ECG, EGCG (2, 38, 40, 49) 
Important natural forms and derivatives
Natural compoundNameSource
Vitamin A Retinyl palmitate, isotretinoin, β-carotene (6–9, 12, 13, 98) 
Isothiocyanate PEITC, BITC, sulforaphane (28, 31, 36) 
Green tea EC, EGC, ECG, EGCG (2, 38, 40, 49) 

Clinical highlights

In 1986, Hong and colleagues were the first to study isotretinoin (13-cis-retinoic acid), a vitamin A derivative, as a treatment for oral leukoplakia (7). The study showed effectiveness of isotretinoin in decreasing the size of lesions and reversing dysplasia in patients by 67% and 54%, respectively, when compared with placebo. Isotretinoin is also effective in patients with oral premalignancies and in preventing recurrences among HNSCC patients who were disease-free after first-line therapy (surgery, radiotherapy, or both; ref. 8). Although there were no differences in recurrence of primary cancers, isotretinoin significantly reduced SPT in a dose-dependent manner (9). In each study, isotretinoin induced mild-to-severe toxicity. Retinyl palmitate and β-carotene are precursors of vitamin A that demonstrated efficacy and minimal toxicity in premalignant lesions (10).

A more recent study compared therapeutic effects of isotretinoin with retinyl palmitate and β-carotene in patients with HNSCC (11). Treatment with isotretinoin had a greater clinical response than the combination of retinyl palmitate with β-carotene or retinyl palmitate alone. However, toxicity remained a significant issue with isotretinoin as 6 patients left the study from toxicity-related issues. Moreover, the study found no significant association between oral premalignant lesion response and survival.

Synergistic interactions

Isotretinoin in combination with IFNα and α-tocopherol (vitamin E) demonstrates the most promise in chemoprevention of oral premalignancies (Table 2). Vitamin E decreases isotretinoin toxicity in addition to having possible chemopreventive effects (12). There has been significant response against laryngeal lesions and advanced dysplasia (6). Further, there has been therapeutic benefit from isotretinoin with surgery or radiotherapy in HNSCC patients with advanced disease (13). A follow-up study confirmed the promising results with longer survival rates and fewer incidence of SPT (12). Mild-to-moderate toxicity, though manageable, was still observed in these patients (12, 13).

Table 2.

The most promising studies of chemopreventive natural compounds in HNSCC

Most promising trials
Natural compoundTypeCompoundResultSource
Vitamin A Clinical Isotretinoin, IFNα, α-tocopherol Improved survival rate and lowered secondary primary tumors (6, 12, 13) 
Curcumin Clinical Curcumin Reduced oral premalignant and high-risk lesions (23, 24) 
Isothiocyanate Preclinical BITC, cisplatin Increase in apoptosis and decrease in HNSCC cell viability (31, 32) 
Green tea Clinical GTE, erlotinib Reduced oral premalignant lesions (47) 
Luteolin Preclinical EGCG, luteolin Induced apoptosis, inhibited growth of xenograft tumors (58) 
Resveratrol Preclinical Resveratrol Induced apoptosis (99) 
Genistein Preclinical Cetuximab, genistein Tumor growth inhibition, apoptosis (83) 
Lycopene Clinical Lycopene Reduction in HNSCC (92) 
Bitter melon Preclinical BME Inhibition of HNSCC growth in mice (93, 95) 
Withaferin A Preclinical Withaferin A Apoptosis of HNSCC cell lines (96) 
Guggulsterone Preclinical Guggulsterone Increased efficacy of erlotinib, cetuximab, and cisplatin (97) 
Most promising trials
Natural compoundTypeCompoundResultSource
Vitamin A Clinical Isotretinoin, IFNα, α-tocopherol Improved survival rate and lowered secondary primary tumors (6, 12, 13) 
Curcumin Clinical Curcumin Reduced oral premalignant and high-risk lesions (23, 24) 
Isothiocyanate Preclinical BITC, cisplatin Increase in apoptosis and decrease in HNSCC cell viability (31, 32) 
Green tea Clinical GTE, erlotinib Reduced oral premalignant lesions (47) 
Luteolin Preclinical EGCG, luteolin Induced apoptosis, inhibited growth of xenograft tumors (58) 
Resveratrol Preclinical Resveratrol Induced apoptosis (99) 
Genistein Preclinical Cetuximab, genistein Tumor growth inhibition, apoptosis (83) 
Lycopene Clinical Lycopene Reduction in HNSCC (92) 
Bitter melon Preclinical BME Inhibition of HNSCC growth in mice (93, 95) 
Withaferin A Preclinical Withaferin A Apoptosis of HNSCC cell lines (96) 
Guggulsterone Preclinical Guggulsterone Increased efficacy of erlotinib, cetuximab, and cisplatin (97) 

Abbreviation: BITC, benzyl isothiocyanate; GTE, green tea extract; EGCG, epigallocatechin-3-gallate; BME, bitter melon extract.

Future considerations

The use of vitamin A derivatives, such as isotretinoin, has long been proven an effective means of chemoprevention in HNSCC. However, toxicity remains a limitation to the utility of the vitamin A derivatives in patients (Table 3). Use of bioadjuvant therapy, such as vitamin E, may improve associated toxicity, though phase III trials are still ongoing (12). Developing novel strategies for delivering these compounds to directly the tumor site could further reduce toxicity in patients.

Table 3.

Current obstacles and solutions for chemopreventive natural compounds in HNSCC

Current
Natural compoundObstaclesSolutionsSource
Vitamin A Toxicity In combination, analogues, bioadjuvant (6–8, 11–13) 
Curcumin Bioavailability Analogues, bioadjuvant, liposomal, nanoparticles, phospholipid complex, in combination (4, 5, 15–17, 21, 23) 
Isothiocyanate Lack of studies specific to HNSCC In combination, analogues (37) 
Green tea Bioavailability In combination, analogues (1, 47, 49) 
Luteolin Bioavailability, lack of studies specific to HNSCC Nanoparticles, in combination (100) 
Resveratrol Bioavailability, lack of studies specific to HNSCC Nanoparticles, in combination, bioadjuvant (61, 70–72) 
Genistein Lack of studies specific to HNSCC In combination (3, 83) 
Lycopene Lack of studies specific to HNSCC In combination, bioadjuvant (3, 84) 
Bitter melon Lack of studies specific to HNSCC Early stages of investigation (93–95) 
Withaferin A Lack of studies specific to HNSCC Early stages of investigation (96) 
Guggulsterone Lack of studies specific to HNSCC Early stages of investigation (97) 
Current
Natural compoundObstaclesSolutionsSource
Vitamin A Toxicity In combination, analogues, bioadjuvant (6–8, 11–13) 
Curcumin Bioavailability Analogues, bioadjuvant, liposomal, nanoparticles, phospholipid complex, in combination (4, 5, 15–17, 21, 23) 
Isothiocyanate Lack of studies specific to HNSCC In combination, analogues (37) 
Green tea Bioavailability In combination, analogues (1, 47, 49) 
Luteolin Bioavailability, lack of studies specific to HNSCC Nanoparticles, in combination (100) 
Resveratrol Bioavailability, lack of studies specific to HNSCC Nanoparticles, in combination, bioadjuvant (61, 70–72) 
Genistein Lack of studies specific to HNSCC In combination (3, 83) 
Lycopene Lack of studies specific to HNSCC In combination, bioadjuvant (3, 84) 
Bitter melon Lack of studies specific to HNSCC Early stages of investigation (93–95) 
Withaferin A Lack of studies specific to HNSCC Early stages of investigation (96) 
Guggulsterone Lack of studies specific to HNSCC Early stages of investigation (97) 

Turmeric, derived from the rhizomes of Curcuma longa, is used as a spice and, particularly in Asia, as a treatment for a number of ailments. Commercially available, turmeric is usually a mixture of three curcuminoids, curcumin (72%), demethoxycurcumin (19%), and bisdemethoxycurcumin (9%). Curcumin, also called diferuloyl methane or bis-a,b–unsaturated b-diketone, is a yellow, hydrophobic polyphenol that has been widely investigated for its antitumor effects in multiple cancer types (2). The major challenge with curcumin lies with its low bioavailability due to limited absorption from the gut.

Several novel packaging strategies including liposomes, polymer nanoparticles, nanogels, and micelles have improved the bioavailability of curcumin (14). Analogues of curcumin also greatly increase the bioavailability, potency, and stability (4, 5, 15, 16). In addition, encapsulation of curcumin and its analogues by lipids and nanoparticles greatly increases bioavailability (17).

Molecular targets and mechanisms of action

Curcumin's anticancer effects mainly result from its various proapoptotic and anti-inflammatory effects. Curcumin induces apoptosis via a number of molecular mechanisms. It causes cell-cycle arrest and inhibits proliferation in HNSCC, via upregulation and activation of p53 and p21 (18, 19).

Curcumin has anti-inflammatory effects that can work to prevent the development and progression of cancer. Curcumin downregulates NF-κB and MAPK pathways, which prevent expression of proinflammatory cytokines and cell signaling necessary for proliferation, metastasis, and angiogenesis (19). Specifically, curcumin-mediated NF-κB inhibition mitigates the expression of proinflammatory cytokines IL6 and IL8. These cytokines are upregulated in patients with HNSCC compared with controls (20). Moreover, curcumin inhibits tumor growth by targeting the EGFR and VEGF (ref. 21; Fig. 2).

Figure 2.

The figure shows the various signaling pathways affected by curcumin. The molecule can act to inhibit a number of pathways that allow for tumor growth and invasion. Curcumin can also lead to upregulation of molecules that lead to cell-cycle arrest in tumor cells. Abbreviations: p53, tumor protein p53; p21, cyclin-dependent kinase inhibitor 1.

Figure 2.

The figure shows the various signaling pathways affected by curcumin. The molecule can act to inhibit a number of pathways that allow for tumor growth and invasion. Curcumin can also lead to upregulation of molecules that lead to cell-cycle arrest in tumor cells. Abbreviations: p53, tumor protein p53; p21, cyclin-dependent kinase inhibitor 1.

Close modal

Clinical highlights

The first clinical trial investigating turmeric and curcumin as anticancerous agents used a 1% curcumin ointment on skin cancer lesions. Reduced pain and lesion size were reported in 10% of patients (22). A more recent phase I clinical trial conducted showed histologic improvements of precancerous lesions in oral cancer patients upon treatment with curcumin, which was not toxic even at doses of 8,000 mg/day (ref. 23; Table 2). However, this trial also clearly showed that curcumin exhibits poor bioavailability, having a mere 1% absorption rate upon oral administration (23). The low plasma and tissue levels of curcumin result from poor absorption due to reduced solubility in water as well as rapid systemic elimination (17).

Synergistic interactions

The chemopreventive effects of curcumin greatly increase when used concomitantly with other natural agents including piperine, genistein, green tea, or embelin. Curcumin also synergistically increased the efficacy of several chemotherapeutic agents including cisplatin, 5-fluorouracil (5-FU), vinca alkaloid, vinorelbine, and gemcitabine (24).

Future considerations

The use of curcumin as a chemopreventive agent in HNSCC is promising due to its effect on multiple molecular pathways essential for cancer progression. Moreover, studies suggest efficacy in combining curcumin with radiotherapy as a first line of treatment in HNSCC (25). Although bioavailability remains a challenge, there are numerous viable approaches to circumvent this problem. Natural derivatives including difluorinated-curcumin (CDF), diphenyl difluoroketone (EF24), and 3, 5-bis (2, 4-difluorobenzylidene)-4-piperidone (DiFiD) also seem to have promise for use in HNSCC as they have been shown to exhibit tumor growth inhibition and increased metabolic stability compared with curcumin in other tumor types (26, 27).

Cruciferous vegetables, including broccoli, kale, and watercress, have various anticancer properties due to high glucosinolate content. Isothiocyanates (ITC) are the most potent component of glucosinolates when isolated via enzymatic hydrolysis. Phenethyl isothiocyanate (PEITC), benzyl isothiocyanate (BITC), and sulforaphane are three naturally occurring ITCs that are being studied as chemopreventive agents (28).

Molecular targets and mechanisms of action

ITCs cause apoptosis and prevent activation of the NF-κB signaling pathway via numerous mechanisms. PEITC and sulforaphane inhibit NF-κB transcriptional activity through multiple methods including preventing dimerization of the molecule and other downstream effects (29). BITC acts to inhibit NF-κB phosphorylation, inducing apoptosis in target cells (30). PEITC also works upstream to decrease EGFR phosphorylation to inactivate NF-κB.

Furthermore, by decreasing EGFR signaling, PEITC can suppress the expression and enzymatic activities of matrix metalloprotease-2 (MMP-2) and MMP-9 (31). MMPs cause extracellular matrix degradation, facilitating tumor metastasis. Both MMP-2 and -9 are expressed in oral cancer and are associated with tumor invasion. BITC induced apoptosis in five HNSCC lines and upregulated antiproliferative activity in cell lines (32).

Clinical highlights

Preclinical trials showed PEITC reduced growth of oral cancer by inducing apoptosis in cancer cells (33). Furthermore, topical application of ITCs induced strong chemopreventive activity against HNSCC in animal models (34). A more recent study demonstrated that ITCs, specifically BITC, inhibit HNSCC migration and invasion. In addition, BITC increased sensitivity to cisplatin treatment in vitro, enhancing the effects of chemotherapy (35). Sulforaphane downregulated various MMPs in HNSCC cell lines, which makes it a potential inhibitor of metastasis (28). A pilot clinical trial using broccoli sprout extracts in 10 healthy volunteers demonstrated target modulation at low micromolar doses in the oral mucosa on oral administration indicating adequate bioavailability, though further investigation is warranted (36).

Future considerations

ITCs hold great potential as chemopreventive agents due to ease of integration into patient diets (37). However, it has been difficult for researchers to create formulations of pure ITCs suitable for clinical investigation, and small changes in their molecular formulas drastically change the mechanisms of action. As clinical trials continue, use of ITCs as adjuvant therapy to conventional anticancer agents seems especially promising due to the substantial increase in efficacy when used in combination (Table 3).

Tea is a widely consumed beverage rich in substances with antioxidant properties. Studies exist investigating both black and green tea as chemopreventive agents, though green tea shows greater efficacy against multiple types of cancer. The health effects of green tea are mostly associated with its polyphenol (PP) content. PPs are reactive metabolites characterized by several hydroxylated aromatic groups and possess powerful antioxidant activity by scavenging a wide range of reactive oxygen, nitrogen, superoxide anions, and metal ions. Green tea extract (GTE) contains four major PPs: epicatechin (EC), epigallocatechin (EGC), epicatechin-3-gallate (ECG), and epigallocatechin-3-gallate (EGCG; ref. 38; Table 1). EGCG is the most abundant PP in green tea and has gained the most attention in anticarcinogenic studies (2).

Molecular targets and mechanisms of action

EGCG has several mechanisms of action, but its antitumor effects stem primarily from suppression of EGFR phosphorylation (39, 40). Up to 90% of HNSCC patients show EGFR overexpression, suggesting GTE could be effective in chemoprevention. EGCG also acts downstream of EGFR to inhibit protein kinase B (Akt) phosphorylation and eventually activation and nuclear translocation of NF-κB (40).

GTE inhibits the VEGFR activation and VEGF secretion, reducing angiogenesis (40, 41). This is a result of inhibition of NF-κB by EGCG (41). EGCG also acts to suppress the MAPK signaling pathway, preventing the transcription of MMPs, specifically MMP-2 and 9, which are expressed in oral cancers (42).

Clinical highlights

Preclinical investigation of GTE chemoprevention started in 1987 with a study that showed topical application of EGCG inhibited tumor formation in mice (43). More recent studies confirm that oral intake of EGCG-rich GTE inhibits cancer development and metastasis in mice models in vitro and in vivo (44). EGCG specifically prevented growth of HNSCC cell lines and enhanced effects of 5-FU (39).

Several phase I trials show similar antitumor effects in humans (45). According to a phase I trial, a dose of 1.0 g TID, equivalent to 7 or 8 cups of green tea, could safely be consumed by patients (46). In patients with high-risk oral premalignant lesions, high-dose GTE for 12 weeks led to higher clinical response rates but showed no significant improvement in cancer-free survival, indicating the need for further studies. Poor bioavailability was reported in the majority of patients in phase II clinical trials (ref. 47; Table 2). The study also assessed the pharmacokinetics of EGCG in the plasma with 500 or 1,000 mg/m2 of oral, thrice-daily GTE dosing. Free EGCG accounted for only 12% to 28% of total EGCG possibly due to poor oral absorption of EGCG.

Synergistic interactions

Multiple synergistic interactions involving GTE have been investigated with some continuing to clinical trials. In preclinical studies, GTE increased the efficacy of many compounds including luteolin, genistein, atorvastatin, curcumin, erlotinib, sulindac, tamoxifen, celecoxib, cisplatin, adriamycin, dacarbazine, lycopene, and EGFR inhibitors in the inhibition of HNSCC growth (3, 40). EGCG also sensitizes multidrug-resistant forms of HNSCC to vincristine sulfate, decreasing tumor growth via downregulation of VEGF in vitro (48). The combination of erlotinib and GTE created a synergistic effect in mice and is currently being studied in a phase I chemoprevention study on patients with premalignant lesions of the head and neck (1).

Future considerations

The use of GTE as a chemopreventive agent in HNSCC seems promising and warrants further studies. There are very few associated toxicities, many synergistic effects, and clear chemopreventive benefit. However, there is a need to improve the bioavailability, standardize the different formulations of GTE, and investigate the effects of greater dosages over longer periods of time (47). Nanoparticle-mediated EGCG delivery enhances bioavailability and reduces toxicity, thus providing an alternate route for EGCG use (ref. 49; Table 3).

Luteolin is flavonoid, a group of PPs that are found in vegetables like cabbage, celery, broccoli, and parsley. Plants rich in flavonoids have been used in traditional East Asian medicine for their anti-inflammatory effects (50). The anticancer effects of luteolin are beginning to be investigated, though the exact biological and molecular mechanisms remain somewhat unclear (51).

Molecular targets and mechanisms of action

Luteolin acts to inhibit activation and phosphorylation of Akt, suppressing VEGFR-mediated angiogenesis and downstream activation of NF-κB (52). It is by blocking the NF-κB pathway and subsequent formation of proinflammatory cytokines like TNFα and IL1 that luteolin produces anti-inflammatory effects.

Luteolin causes cell-cycle arrest due to decreased CDK4/6 activity. CDK4/6 form a complex with cyclin D1, which is downregulated via suppression of the Akt signaling pathway (53). The Akt pathway plays a major role in cell-cycle progression and is often upregulated in many forms of cancer, including HNSCC (54).

Clinical highlights

Preclinical studies showed luteolin causes apoptosis of HNSCC cell lines and inhibits tumor growth in mice (55). A similar study found luteolin decreased both the incidence and tumor volume of lung cancer significantly compared with controls in mice (56). Akt expression was downregulated in a dose-dependent manner in mice. Surprisingly, treated mice showed no decrease in body weight or other cytotoxic effects compared with control mice (55). Delivery of luteolin in nanoparticles significantly inhibited growth of HNSCC tumors in vitro and in vivo and showed increased efficacy compared with free luteolin, which displays poor bioavailability due to poor solubility (57). Despite these encouraging results, no clinical trials have begun to investigate luteolin in humans.

Synergistic interactions

Luteolin improves the cytotoxic effects of many chemotherapy and chemopreventive treatments including cisplatin, doxorubicin, TNFα, paclitaxel, and EGCG in various types of cancer (58). Preclinical trials for HNSCC show combination treatment of luteolin with paclitaxel-enhanced inhibition of tumor growth compared with paclitaxel alone (59).

Future considerations

Luteolin is a natural agent that still requires investigation to be deemed effective in humans. One major obstacle to the clinical application of luteolin is its low systemic bioavailability due to metabolism in the liver and intestine (3). However, the epithelium of the oral cavity can absorb luteolin directly, and delivery with nanoparticles may solve other problems with bioavailability that may arise (60). However, phase I and II trials investigating the role of luteolin in chemoprevention of any cancers have still not begun.

The compound resveratrol (3,5,4′-trihydroxystilbene) is a naturally occurring phytoalexin found in grapes, peanuts, and mulberries (61). High levels of resveratrol are found in the skin of grapes and in red wine (3). Resveratrol is widely considered the cardioprotective factor in red wine and is being investigated for anticancer properties (62).

Molecular targets/mechanisms of action

Resveratrol targets multiple signaling pathways that facilitate cell growth, inflammation, and cell survival. Resveratrol increases expression and activation of p53 and elevation in p21 levels (62). This causes cell-cycle arrest and apoptosis in cells. By suppressing phosphorylation of STAT3, resveratrol also inhibits the JAK/STAT pathway of signaling that is constitutively activated in HNSCC cells, causing cell death (63). Furthermore, resveratrol decreases NF-κB activation and nuclear translocation of the p65 subunit in a variety of cell types (62). Resveratrol also acts upstream of NF-κB to suppress Akt activity and signaling (64). In order to reduce inflammation, resveratrol inhibits the MAPK signaling pathway, preventing formation of proinflammatory cytokines (18).

Clinical highlights

Chemopreventive studies involving resveratrol began after 1997 when a study found topical application of the agent prevented tumor formation in mice (65). Subsequent preclinical studies confirmed similar antitumor effects in various cancer cell lines, including HNSCC cells (63). One study showed resveratrol inhibited tumor growth in mice; however, efficacy of resveratrol in humans proves more complicated to confirm due to poor bioavailability (66). When consumed orally, 70% to 80% of resveratrol is absorbed by the intestines (67). Further, after administration of 5 g daily for 29 days, trans-resveratrol was detected in the plasma at concentrations as high as 4 μmol/L. Mechanisms to increase bioavailability are under investigation and include packaging within nanoparticles and coadministration with curcumin (68, 69). In humans, resveratrol toxicity is minimal, and one phase I study showed even amounts as high as 5 g were safe in healthy patients (3).

Synergistic interactions

Resveratrol has many synergistic interactions with chemopreventive compounds including EGCG, vitamin E, genistein, cisplatin, doxorubicin, FU, paclitaxel, and curcumin (3). In HNSCC, the combination of resveratrol and curcumin was more effective at inhibiting cancer growth in preclinical models than curcumin alone (70). 5-FU and resveratrol also showed a synergistic antitumor effect in HNSCC cell lines (71, 72). Resveratrol enhanced sensitivity to chemotherapy and radiotherapy in HNSCC cells (73).

Future considerations

The use of resveratrol shows promise as a chemopreventive agent against HNSCC, especially when used as adjuvant therapy with other chemotherapeutic agents. Clinical trials are currently underway to further investigate the effects of resveratrol in patients, and studies to increase bioavailability may improve efficacy.

The natural compound Genistein (4,5,7-trihydroxyisoflavone) is a phytoestrogen abundant in soybeans and other legumes (3, 74). There have been no clinical studies that examine the effects of genistein on HNSCC. Epidemiologic studies demonstrated efficacy of genistein intake on breast, prostate, and colorectal cancers (75). However, habitual consumption of soy products showed no significant effect on the risk of HNSCC in Chinese adults, though this study had many significant limitations (76).

Molecular targets/mechanisms of action

Several studies revealed the anticancer effects of the consumption of soy products. By affecting multiple pathways, genistein has antiproliferative and antiangiogenic effects (3). Genistein significantly downregulates MAPK and Akt signaling, inhibiting VEGF-mediated angiogenesis in HNSCC cells (77). It also acts downstream to inhibit NF-κB and thus cell proliferation (77). Other antiproliferative effects of genistein result from decreased phosphorylation of the insulin-like growth factor receptor (IGFR) and IGF signaling, inhibiting cell growth (78). Genistein acts to induce cell-cycle arrest and apoptosis by activating p53 and increasing p21 expression (79). Secretion of MMP-2 and -9 decreases with genistein, inhibiting tumor invasion and migration capabilities (74).

Clinical highlights

Despite numerous molecular targets, preclinical trials involving genistein and HNSCC are not conclusive in showing efficacy as a chemopreventive agent. Low concentrations of whole soy protein extract significantly inhibited oral cancer growth in cell lines (80). However, genistein itself varies in its efficacy between studies. One study showed purified genistein had no effect on the tumor growth and metastasis but inhibited tumor invasion (81). A more recent study contradicted previous results, showing genistein inhibited proliferation of HNSCC cell lines (82), thus necessitating further research to confirm genistein efficacy.

Synergistic interactions

As genistein might have its greatest utility in combination, it has many synergistic interactions with chemopreventive agents including EGCG, letrozole, docetaxel, resveratrol, lycopene, vitamin D, tamoxifen, paclitaxel, cisplatin, erlotinib, gemcitabine, doxorubicin, FU, camptothecin, bleomycin, and cetuximab (83). One study combined cetuximab, an anti-EGFR monoclonal antibody, with genistein to evaluate inhibition of the EGFR pathway. Even at low concentrations, the combination resulted in additive growth inhibition and increased apoptosis compared with single-agent exposure (ref. 83; Table 2).

Future considerations

Genistein seems to hold its most promise as an adjuvant therapy. However, further preclinical and eventually clinical studies may prove its efficacy as a single agent in chemoprevention of HNSCC.

The natural compound lycopene is a red-colored carotenoid and is predominantly found in tomatoes (3, 84). Of the carotenoids, lycopene is the most abundant in fruits and vegetables and the most promising in chemoprevention. Various epidemiologic studies show dietary supplementation with lycopene decreases risk of cancer, and effected molecular targets are numerous and diverse (85).

Molecular targets/mechanisms of action

Lycopene acts at multiple points to inhibit VEGF-mediated angiogenesis. Lycopene suppresses Akt activation by preventing phosphorylation of the molecule (86). Further downstream, lycopene directly inhibits the NF-κB signaling pathway by preventing nuclear translocation and NF-κB DNA binding (87). By decreasing plasma levels and activity of MMP-2 and -9, lycopene also acts to inhibit invasion and metastasis (88).

Clinical highlights

Preclinical studies show that lycopene decreased HNSCC cell growth, induced apoptosis in cells, and prevented tumor invasion (89). Lycopene worked to inhibit the Akt signaling pathway in a dose-dependent manner.

When used in humans, lycopene was safe and more effective in the management of oral leukoplakia in patients than placebo (90). The treatment of oral premalignant lesions with lycopene was associated with significant clinical and histologic responses compared with placebo or absence of treatment against HNSCC (91). Lycopene significantly reduced multiple forms of HNSCC including laryngeal, oral, and pharyngeal cancer (ref. 91; Table 2). Phase II trials of lycopene have shown effectiveness in decreasing prostate cancer growth, suggesting it may be useful in prevention and treatment in other forms of cancer (92).

Future considerations

Much preclinical and clinical evidence gives promise to the use of lycopene as an effective chemopreventive agent against HNSCC. There is little associated toxicity, and it shows significant response against other forms of cancer. However, the need exists for more mechanistic studies and randomized controlled trials to confirm the benefits of lycopene and its use in routine prevention and management of HNSCC (ref. 84; Table 3).

Bitter melon, which is grown primarily in Asia, Africa, and South America, is a plant that has been used in traditional medicine practices, especially for patients with diabetes, and is beginning to be investigated as a chemopreventive agent. Preclinical studies show that bitter melon extract (BME) inhibited HNSCC growth in vitro and in vivo in mice by modulating immune-regulatory mechanisms (93–95). Exact molecular mechanisms of action are starting to be elucidated, but no clinical trials investigating antitumor effects of bitter melon have begun.

Numerous medicinal plant–derived compounds are being investigated for their anticancer properties. Such compounds include withaferin A, which is extracted from Vassobia breviflora in Latin America. Preclinical studies show antiproliferative effects of withaferin A on HNSCC cell lines by interacting with Akt and inducing apoptosis (96). Another such compound is guggulsterone, which is widely available and well-tolerated. Guggulsterone enhances efficacy of chemotherapy drugs including erlotinib, cetuximab, and cisplatin by decreasing expression of STAT-3 (97). These compounds are only two examples of extracts from plants that are in studies for HNSCC treatment, though no clinical trials are in effect.

HNSCC claims more than 300,000 lives each year worldwide, and with poor overall survival rates (<50%) using current therapies. Smoking, alcohol use, and HPV infection are the largest risk factors for HNSCC, thus primary prevention focuses on mitigating risk factors. Even in lieu of improved management of risk factors, HNSCC will remain dangerous through genetic predispositions and prior field cancerization. As treatment with surgery, chemotherapy, and radiotherapy often cause severe morbidity from damage to the upper aerodigestive tract, the prevention and early diagnosis of high-risk premalignant lesions should be emphasized. The use of natural compounds in the chemoprevention of HNSCC shows promise in reversing these abysmal trends (98–100).

Natural compounds show promise as chemopreventive agents in HNSCC because of their tolerability, safety, low toxicity, antioxidant properties, and general acceptance as dietary supplements (3). Moreover, many studies have displayed the potential utility of natural compounds against HNSCC.

Depending on the compound, however, specific challenges exist including low bioavailability, high toxicity, and few molecular targets. There are myriad solutions to circumvent these problems including the use of chemical analogues, adjuvant therapies, and nanoparticle delivery mechanisms. Currently, this field remains in its infancy, and its biggest challenge is a shortage of research on chemopreventive natural compounds specific to HNSCC. In order to find safe and effective compounds, clinical trials must continue for the different natural agents.

No potential conflicts of interest were disclosed.

This work was supported by the University of Kansas Cancer Center's CCSG (1-P30-CA168524-02) and Kansas Intellectual and Developmental Disabilities Research Center (NIH U54 HD 090216) at the University of Kansas Medical Center. The authors acknowledge artwork by Phil Shafer and Levi Arnold, University of Kansas Medical Center.

1.
Saba
NF
,
Haigentz
M
 Jr
,
Vermorken
JB
,
Strojan
P
,
Bossi
P
,
Rinaldo
A
, et al
Prevention of head and neck squamous cell carcinoma: removing the “chemo” from “chemoprevention”
.
Oral Oncol
2015
;
51
:
112
8
.
2.
Rahman
MA
,
Amin
AR
,
Shin
DM
. 
Chemopreventive potential of natural compounds in head and neck cancer
.
Nutr Cancer
2010
;
62
:
973
87
.
3.
Amin
AR
,
Kucuk
O
,
Khuri
FR
,
Shin
DM
. 
Perspectives for cancer prevention with natural compounds
.
J Clin Oncol
2009
;
27
:
2712
25
.
4.
Zhu
S
,
Moore
TW
,
Lin
X
,
Morii
N
,
Mancini
A
,
Howard
RB
, et al
Synthetic curcumin analog EF31 inhibits the growth of head and neck squamous cell carcinoma xenografts
.
Integrative Biol
2012
;
4
:
633
40
.
5.
Gagliardi
S
,
Ghirmai
S
,
Abel
KJ
,
Lanier
M
,
Gardai
SJ
,
Lee
C
, et al
Evaluation in vitro of synthetic curcumins as agents promoting monocytic gene expression related to beta-amyloid clearance
.
Chem Res Toxicol
2012
;
25
:
101
12
.
6.
Papadimitrakopoulou
VA
,
Clayman
GL
,
Shin
DM
,
Myers
JN
,
Gillenwater
AM
,
Goepfert
H
, et al
Biochemoprevention for dysplastic lesions of the upper aerodigestive tract
.
Arch Otolaryngol Head Neck Surg
1999
;
125
:
1083
9
.
7.
Hong
WK
,
Endicott
J
,
Itri
LM
,
Doos
W
,
Batsakis
JG
,
Bell
R
, et al
13-cis-retinoic acid in the treatment of oral leukoplakia
.
N Engl J Med
1986
;
315
:
1501
5
.
8.
Lippman
SM
,
Batsakis
JG
,
Toth
BB
,
Weber
RS
,
Lee
JJ
,
Martin
JW
, et al
Comparison of low-dose isotretinoin with beta carotene to prevent oral carcinogenesis
.
N Engl J Med
1993
;
328
:
15
20
.
9.
Perry
CF
,
Stevens
M
,
Rabie
I
,
Yarker
ME
,
Cochrane
J
,
Perry
E
, et al
Chemoprevention of head and neck cancer with retinoids: a negative result
.
Arch Otolaryngol Head Neck Surg
2005
;
131
:
198
203
.
10.
Garewal
HS
,
Katz
RV
,
Meyskens
F
,
Pitcock
J
,
Morse
D
,
Friedman
S
, et al
Beta-carotene produces sustained remissions in patients with oral leukoplakia: results of a multicenter prospective trial
.
Arch Otolaryngol Head Neck Surg
1999
;
125
:
1305
10
.
11.
Papadimitrakopoulou
VA
,
Lee
JJ
,
William
WN
 Jr
,
Martin
JW
,
Thomas
M
,
Kim
ES
, et al
Randomized trial of 13-cis retinoic acid compared with retinyl palmitate with or without beta-carotene in oral premalignancy
.
J Clin Oncol
2009
;
27
:
599
604
.
12.
Seixas-Silva
JA
 Jr
,
Richards
T
,
Khuri
FR
,
Wieand
HS
,
Kim
E
,
Murphy
B
, et al
Phase 2 bioadjuvant study of interferon alfa-2a, isotretinoin, and vitamin E in locally advanced squamous cell carcinoma of the head and neck: long-term follow-up
.
Arch Otolaryngol Head Neck Surg
2005
;
131
:
304
7
.
13.
Shin
DM
,
Khuri
FR
,
Murphy
B
,
Garden
AS
,
Clayman
G
,
Francisco
M
, et al
Combined interferon-alfa, 13-cis-retinoic acid, and alpha-tocopherol in locally advanced head and neck squamous cell carcinoma: novel bioadjuvant phase II trial
.
J Clin Oncol
2001
;
19
:
3010
7
.
14.
Panda
AK
,
Chakraborty
D
,
Sarkar
I
,
Khan
T
,
Sa
G
. 
New insights into therapeutic activity and anticancer properties of curcumin
.
J Exp Pharmacol
2017
;
9
:
31
45
.
15.
Kudo
C
,
Yamakoshi
H
,
Sato
A
,
Nanjo
H
,
Ohori
H
,
Ishioka
C
, et al
Synthesis of 86 species of 1,5-diaryl-3-oxo-1,4-pentadienes analogs of curcumin can yield a good lead in vivo
.
BMC Pharmacol
2011
;
11
:
4
.
16.
Tamvakopoulos
C
,
Dimas
K
,
Sofianos
ZD
,
Hatziantoniou
S
,
Han
Z
,
Liu
ZL
, et al
Metabolism and anticancer activity of the curcumin analogue, dimethoxycurcumin
.
Clin Cancer Res
2007
;
13
:
1269
77
.
17.
Belkacemi
A
,
Doggui
S
,
Dao
L
,
Ramassamy
C
. 
Challenges associated with curcumin therapy in Alzheimer disease
.
Exp Rev Mol Med
2011
;
13
:
e34
.
18.
Hu
A
,
Huang
J-J
,
Zhang
J-F
,
Dai
W-J
,
Li
R-L
,
Lu
Z-Y
, et al
Curcumin induces G2/M cell cycle arrest and apoptosis of head and neck squamous cell carcinoma in vitro and in vivo through ATM/Chk2/p53-dependent pathway
.
Oncotarget
2017
;
8
:
50747
60
.
19.
Lee
AY-L
,
Fan
C-C
,
Chen
Y-A
,
Cheng
C-W
,
Sung
Y-J
,
Hsu
C-P
, et al
Curcumin inhibits invasiveness and epithelial-mesenchymal transition in oral squamous cell carcinoma through reducing matrix metalloproteinase 2, 9 and modulating p53-E-cadherin pathway
.
Integrat Cancer Ther
2015
;
14
:
484
90
.
20.
Cohen
AN
,
Veena
MS
,
Srivatsan
ES
. 
Suppression of interleukin 6 and 8 production in head and neck cancer cells with curcumin via inhibition of Iκβ kinase
.
Arch Otolaryngol Head Neck Surg
2009
;
135
:
190
7
.
21.
Subramaniam
D
,
Ramalingam
S
,
Linehan
DC
,
Dieckgraefe
BK
,
Postier
RG
,
Houchen
CW
, et al
RNA binding protein CUGBP2/CELF2 mediates curcumin-induced mitotic catastrophe of pancreatic cancer cells
.
PLOS ONE
2011
;
6
:
e16958
.
22.
Kuttan
R
,
Sudheeran
PC
,
Josph
CD
. 
Turmeric and curcumin as topical agents in cancer therapy
.
Tumori
1987
;
73
:
29
31
.
23.
Cheng
AL
,
Hsu
CH
,
Lin
JK
,
Hsu
MM
,
Ho
YF
,
Shen
TS
, et al
Phase I clinical trial of curcumin, a chemopreventive agent, in patients with high-risk or pre-malignant lesions
.
Anticancer Res
2001
;
21
:
2895
900
.
24.
Duarte
VM
,
Han
E
,
Veena
MS
,
Salvado
A
,
Suh
JD
,
Liang
LJ
, et al
Curcumin enhances the effect of cisplatin in suppression of head and neck squamous cell carcinoma via inhibition of IKKbeta protein of the NFkappaB pathway
.
Mol Cancer Ther
2010
;
9
:
2665
75
.
25.
Tuttle
S
,
Hertan
L
,
Daurio
N
,
Porter
S
,
Kaushick
C
,
Li
D
, et al
The chemopreventive and clinically used agent curcumin sensitizes HPV (−) but not HPV (+) HNSCC to ionizing radiation, in vitro and in a mouse orthotopic model
.
Cancer Biol Ther
2012
;
13
:
575
84
.
26.
Padhye
S
,
Banerjee
S
,
Chavan
D
,
Pandye
S
,
Swamy
K
,
Ali
S
, et al
Fluorocurcumins as cyclooxygenase-2 inhibitor: molecular docking, pharmacokinetics and tissue distribution in mice
.
Pharm Res
2009
;
26
:
2438
45
.
27.
Subramaniam
D
,
Nicholes
ND
,
Dhar
A
,
Umar
S
,
Awasthi
V
,
Welch
DR
, et al
3, 5-bis (2, 4-difluorobenzylidene)-4-piperidone, a novel compound that affects pancreatic cancer growth and angiogenesis
.
Mol Cancer Ther
2011
;
10
:
2146
56
.
28.
Jee
HG
,
Lee
KE
,
Kim
JB
,
Shin
HK
,
Youn
YK
. 
Sulforaphane inhibits oral carcinoma cell migration and invasion in vitro
.
Phytother Res
2011
;
25
:
1623
8
.
29.
Zhu
J
,
Ghosh
A
,
Coyle
EM
,
Lee
J
,
Hahm
E-R
,
Singh
SV
, et al
Differential effects of phenethyl isothiocyanate and D,L-sulforaphane on TLR3 signaling
.
J Immunol
2013
;
190
:
4400
7
.
30.
Kumar
G
,
Tuli
HS
,
Mittal
S
,
Shandilya
JK
,
Tiwari
A
,
Sandhu
SS
. 
Isothiocyanates: a class of bioactive metabolites with chemopreventive potential
.
Tumour Biol
2015
;
36
:
4005
16
.
31.
Chen
HJ
,
Lin
CM
,
Lee
CY
,
Shih
NC
,
Amagaya
S
,
Lin
YC
, et al
Phenethyl isothiocyanate suppresses EGF-stimulated SAS human oral squamous carcinoma cell invasion by targeting EGF receptor signaling
.
Int J Oncol
2013
;
43
:
629
37
.
32.
Lui
VW
,
Wentzel
AL
,
Xiao
D
,
Lew
KL
,
Singh
SV
,
Grandis
JR
. 
Requirement of a carbon spacer in benzyl isothiocyanate-mediated cytotoxicity and MAPK activation in head and neck squamous cell carcinoma
.
Carcinogenesis
2003
;
24
:
1705
12
.
33.
Huong
LD
,
Shin
JA
,
Choi
ES
,
Cho
NP
,
Kim
HM
,
Leem
DH
, et al
β-Phenethyl isothiocyanate induces death receptor 5 to induce apoptosis in human oral cancer cells via p38
.
Oral Dis
2012
;
18
:
513
9
.
34.
Solt
DB
,
Chang
K-w
,
Helenowski
I
,
Rademaker
AW
. 
Phenethyl isothiocyanate inhibits nitrosamine carcinogenesis in a model for study of oral cancer chemoprevention
.
Cancer Lett
2003
;
202
:
147
52
.
35.
Wolf
MA
,
Claudio
PP
. 
Benzyl isothiocyanate inhibits HNSCC cell migration and invasion, and sensitizes HNSCC cells to cisplatin
.
Nutr Cancer
2014
;
66
:
285
94
.
36.
Bauman
JE
,
Zang
Y
,
Sen
M
,
Li
C
,
Wang
L
,
Egner
PA
, et al
Prevention of carcinogen-induced oral cancer by sulforaphane
.
Cancer Prev Res
2016
;
9
:
547
57
.
37.
Gupta
P
,
Wright
SE
,
Kim
SH
,
Srivastava
SK
. 
Phenethyl isothiocyanate: a comprehensive review of anti-cancer mechanisms
.
Biochim Biophys Acta
2014
;
1846
:
405
24
.
38.
Khuri
FR
,
Shin
DM
. 
Head and neck cancer chemoprevention gets a shot in the arm
.
J Clin Oncol
2008
;
26
:
345
7
.
39.
Masuda
M
,
Suzui
M
,
Weinstein
IB
. 
Effects of epigallocatechin-3-gallate on growth, epidermal growth factor receptor signaling pathways, gene expression, and chemosensitivity in human head and neck squamous cell carcinoma cell lines
.
Clin Cancer Res
2001
;
7
:
4220
9
.
40.
Kim
JW
,
Amin
AR
,
Shin
DM
. 
Chemoprevention of head and neck cancer with green tea polyphenols
.
Cancer Prev Res
2010
;
3
:
900
9
.
41.
Masuda
M
,
Suzui
M
,
Lim
JT
,
Deguchi
A
,
Soh
JW
,
Weinstein
IB
. 
Epigallocatechin-3-gallate decreases VEGF production in head and neck and breast carcinoma cells by inhibiting EGFR-related pathways of signal transduction
.
J Exp Ther Oncol
2002
;
2
:
350
9
.
42.
Ho
Y-C
,
Yang
S-F
,
Peng
C-Y
,
Chou
M-Y
,
Chang
Y-C
. 
Epigallocatechin-3-gallate inhibits the invasion of human oral cancer cells and decreases the productions of matrix metalloproteinases and urokinase-plasminogen activator
.
J Oral Pathol Med
2007
;
36
:
588
93
.
43.
Yoshizawa
S
,
Horiuchi
T
,
Fujiki
H
,
Yoshida
T
,
Okuda
T
,
Sugimura
T
. 
Antitumor promoting activity of (−)-epigallocatechin gallate, the main constituent of “Tannin” in green tea
.
Phytother Res
1987
;
1
:
44
7
.
44.
Baliga
MS
,
Meleth
S
,
Katiyar
SK
. 
Growth inhibitory and antimetastatic effect of green tea polyphenols on metastasis-specific mouse mammary carcinoma 4T1 Cells In vitro and In vivo systems
.
Clin Cancer Res
2005
;
11
:
1918
27
.
45.
Shanafelt
TD
,
Lee
YK
,
Call
TG
,
Nowakowski
GS
,
Dingli
D
,
Zent
CS
, et al
Clinical effects of oral green tea extracts in four patients with low grade B-cell malignancies
.
Leukemia Res
2006
;
30
:
707
12
.
46.
Pisters
KM
,
Newman
RA
,
Coldman
B
,
Shin
DM
,
Khuri
FR
,
Hong
WK
, et al
Phase I trial of oral green tea extract in adult patients with solid tumors
.
J Clin Oncol
2001
;
19
:
1830
8
.
47.
Tsao
AS
,
Liu
D
,
Martin
J
,
Tang
XM
,
Lee
JJ
,
El-Naggar
AK
, et al
Phase II randomized, placebo-controlled trial of green tea extract in patients with high-risk oral premalignant lesions
.
Cancer Prev Res
2009
;
2
:
931
41
.
48.
Hu
Y
,
Chen
L
,
Zhang
G
,
Li
L
,
Liang
G
. 
Epigallocatechin-3-gallate sensitizes multidrug-resistant oral squamous carcinoma cells to vincristine sulfate involving angiogenesis inhibition via down-regulating VEGF in vivo
.
FASEB J
2017
;
31
:
790.20
.
49.
Siddiqui
IA
,
Adhami
VM
,
Bharali
DJ
,
Hafeez
BB
,
Asim
M
,
Khwaja
SI
, et al
Introducing nanochemoprevention as a novel approach for cancer control: proof of principle with green tea polyphenol epigallocatechin-3-gallate
.
Cancer Res
2009
;
69
:
1712
6
.
50.
Lin
Y
,
Shi
R
,
Wang
X
,
Shen
H-M
. 
Luteolin, a flavonoid with potentials for cancer prevention and therapy
.
Curr Cancer Drug Targets
2008
;
8
:
634
46
.
51.
Zhang
H
,
Li
X
,
Zhang
Y
,
Luan
X
. 
Luteolin induces apoptosis by activating Fas signaling pathway at the receptor level in laryngeal squamous cell line Hep-2 cells
.
Eur Arch Otorhinolaryngol
2014
;
271
:
1653
9
.
52.
Seo
Y
,
Ryu
K
,
Park
J
,
Jeon
D-k
,
Jo
S
,
Lee
HK
, et al
Inhibition of ANO1 by luteolin and its cytotoxicity in human prostate cancer PC-3 cells
.
PLOS ONE
2017
;
12
:
e0174935
.
53.
Ong
C-S
,
Zhou
J
,
Ong
C-N
,
Shen
H-M
. 
Luteolin induces G1 arrest in human nasopharyngeal carcinoma cells via the Akt–GSK-3β–Cyclin D1 pathway
.
Cancer Lett
2010
;
298
:
167
75
.
54.
Chou
J
,
Lin
Y-C
,
Kim
J
,
You
L
,
Xu
Z
,
He
B
, et al
Nasopharyngeal carcinoma—review of the molecular mechanisms of tumorigenesis
.
Head Neck
2008
;
30
:
946
63
.
55.
Chen
P
,
Zhang
J-Y
,
Sha
B-B
,
Ma
Y-E
,
Hu
T
,
Ma
Y-C
, et al
Luteolin inhibits cell proliferation and induces cell apoptosis via down-regulation of mitochondrial membrane potential in esophageal carcinoma cells EC1 and KYSE450
.
Oncotarget
2017
;
8
:
27471
80
.
56.
Kim
J-H
,
Lee
E-O
,
Lee
H-J
,
Ku
J-S
,
Lee
M-H
,
Yang
D-C
, et al
Caspase Activation and extracellular signal-regulated kinase/akt inhibition were involved in luteolin-induced apoptosis in lewis lung carcinoma cells
.
Ann New York Acad Sci
2007
;
1095
:
598
611
.
57.
Majumdar
D
,
Jung
K-H
,
Zhang
H
,
Nannapaneni
S
,
Wang
X
,
Amin
ARMR
, et al
Luteolin nanoparticle in chemoprevention – in vitro and in vivo anticancer activity
.
Cancer Prev Res
2014
;
7
:
65
73
.
58.
Amin
AR
,
Wang
D
,
Zhang
H
,
Peng
S
,
Shin
HJ
,
Brandes
JC
, et al
Enhanced anti-tumor activity by the combination of the natural compounds (−)-epigallocatechin-3-gallate and luteolin: potential role of p53
.
J Biol Chem
2010
;
285
:
34557
65
.
59.
Yang
S-F
,
Yang
W-E
,
Chang
H-R
,
Chu
S-C
,
Hsieh
Y-S
. 
Luteolin induces apoptosis in oral squamous cancer cells
.
J Dental Res
2008
;
87
:
401
6
.
60.
Walle
T
,
Browning
AM
,
Steed
LL
,
Reed
SG
,
Walle
UK
. 
Flavonoid glucosides are hydrolyzed and thus activated in the oral cavity in humans
.
J Nutr
2005
;
135
:
48
52
.
61.
Shrikanta
A
,
Kumar
A
,
Govindaswamy
V
. 
Resveratrol content and antioxidant properties of underutilized fruits.
J Food Sci Technol
2015
;
52
:
383
90
.
62.
Aggarwal
BB
,
Bhardwaj
A
,
Aggarwal
RS
,
Seeram
NP
,
Shishodia
S
,
Takada
Y
. 
Role of resveratrol in prevention and therapy of cancer: preclinical and clinical studies
.
Anticancer Res
2004
;
24
:
2783
840
.
63.
Baek
SH
,
Ko
J-H
,
Lee
H
,
Jung
J
,
Kong
M
,
Lee
J-w
, et al
Resveratrol inhibits STAT3 signaling pathway through the induction of SOCS-1: Role in apoptosis induction and radiosensitization in head and neck tumor cells
.
Phytomedicine
2016
;
23
:
566
77
.
64.
Sheth
S
,
Jajoo
S
,
Kaur
T
,
Mukherjea
D
,
Sheehan
K
,
Rybak
LP
, et al
Resveratrol reduces prostate cancer growth and metastasis by inhibiting the Akt/MicroRNA-21 pathway
.
PLOS ONE
2012
;
7
:
e51655
.
65.
Jang
M
,
Cai
L
,
Udeani
GO
,
Slowing
KV
,
Thomas
CF
,
Beecher
CWW
, et al
Cancer chemopreventive activity of resveratrol, a natural product derived from grapes
.
Science
1997
;
275
:
218
20
.
66.
Wu
S-L
,
Sun
Z-J
,
Yu
L
,
Meng
K-W
,
Qin
X-L
,
Pan
C-E
. 
Effect of resveratrol and in combination with 5-FU on murine liver cancer
.
World J Gastroenterol
2004
;
10
:
3048
52
.
67.
Carter
LG
,
D'Orazio
JA
,
Pearson
KJ
. 
Resveratrol and cancer: focus on in vivo evidence
.
Endocr Relat Cancer
2014
;
21
:
R209
R25
.
68.
Geng
T
,
Zhao
X
,
Ma
M
,
Zhu
G
,
Yin
L
. 
Resveratrol-loaded albumin nanoparticles with prolonged blood circulation and improved biocompatibility for highly effective targeted pancreatic tumor therapy
.
Nanoscale Res Lett
2017
;
12
:
437
.
69.
Ge
S
,
Yin
T
,
Xu
B
,
Gao
S
,
Hu
M
. 
Curcumin affects phase II disposition of resveratrol through inhibiting efflux transporters MRP2 and BCRP
.
Pharm Res
2016
;
33
:
590
602
.
70.
Masuelli
L
,
Di Stefano
E
,
Fantini
M
,
Mattera
R
,
Benvenuto
M
,
Marzocchella
L
, et al
Resveratrol potentiates the in vitro and in vivo anti-tumoral effects of curcumin in head and neck carcinomas
.
Oncotarget
2014
;
5
:
10745
62
.
71.
Heiduschka
G
,
Bigenzahn
J
,
Brunner
M
,
Thurnher
D
. 
Resveratrol synergistically enhances the effect of etoposide in HNSCC cell lines
.
Acta Otolaryngol
2014
;
134
:
1071
8
.
72.
Mohan
A
,
Narayanan
S
,
Sethuraman
S
,
Krishnan
UM
. 
Novel resveratrol and 5-fluorouracil coencapsulated in PEGylated nanoliposomes improve chemotherapeutic efficacy of combination against head and neck squamous cell carcinoma
.
BioMed Res Int
2014
;
2014
:
424239
.
73.
Mikami
S
,
Ota
I
,
Masui
T
,
Itaya-Hironaka
A
,
Shobatake
R
,
Okamoto
H
, et al
Effect of resveratrol on cancer progression through the REG expression pathway in head and neck cancer cells
.
Int J Oncol
2016
;
49
:
1553
60
.
74.
Alhasan
SA
,
Aranha
O
,
Sarkar
FH
. 
Genistein elicits pleiotropic molecular effects on head and neck cancer cells
.
Clin Cancer Res
2001
;
7
:
4174
81
.
75.
Hwang
YW
,
Kim
SY
,
Jee
SH
,
Kim
YN
,
Nam
CM
. 
Soy food consumption and risk of prostate cancer: a meta-analysis of observational studies
.
Nutr Cancer
2009
;
61
:
598
606
.
76.
Liu
YT
,
Fan
YY
,
Xu
CH
,
Lin
XL
,
Lu
YK
,
Zhang
XL
, et al
Habitual consumption of soy products and risk of nasopharyngeal carcinoma in Chinese adults: a case-control study
.
PloS One
2013
;
8
:
e77822
.
77.
Zhang
J
,
Su
H
,
Li
Q
,
Li
J
,
Zhao
Q
. 
Genistein decreases A549 cell viability via inhibition of the PI3K/AKT/HIF1alpha/VEGF and NFkappaB/COX2 signaling pathways
.
Mol Med Rep
2017
;
15
:
2296
302
.
78.
Lee
J
,
Ju
J
,
Park
S
,
Hong
SJ
,
Yoon
S
. 
Inhibition of IGF-1 signaling by genistein: modulation of E-cadherin expression and downregulation of beta-catenin signaling in hormone refractory PC-3 prostate cancer cells
.
Nutr Cancer
2012
;
64
:
153
62
.
79.
Zhang
Z
,
Wang
C-Z
,
Du
G-J
,
Qi
L-W
,
Calway
T
,
He
T-C
, et al
Genistein induces G2/M cell cycle arrest and apoptosis via ATM/p53-dependent pathway in human colon cancer cells
.
Int J Oncol
2013
;
43
:
289
96
.
80.
Kingsley
K
,
Truong
K
,
Low
E
,
Hill
CK
,
Chokshi
SB
,
Phipps
D
, et al
Soy protein extract (SPE) exhibits differential in vitro cell proliferation effects in oral cancer and normal cell lines
.
J Diet Suppl
2011
;
8
:
169
88
.
81.
Myoung
H
,
Hong
SP
,
Yun
PY
,
Lee
JH
,
Kim
MJ
. 
Anti-cancer effect of genistein in oral squamous cell carcinoma with respect to angiogenesis and in vitro invasion
.
Cancer Sci
2003
;
94
:
215
20
.
82.
Walle
T
,
Browning
AM
,
Steed
LL
,
Reed
SG
,
Walle
UK
. 
Flavonoid glucosides are hydrolyzed and thus activated in the oral cavity in humans
.
J Nutr
2005
;
135
:
48
52
.
83.
Park
SJ
,
Kim
MJ
,
Kim
YK
,
Kim
SM
,
Park
JY
,
Myoung
H
. 
Combined cetuximab and genistein treatment shows additive anti-cancer effect on oral squamous cell carcinoma
.
Cancer Lett
2010
;
292
:
54
63
.
84.
Lu
R
,
Dan
H
,
Wu
R
,
Meng
W
,
Liu
N
,
Jin
X
, et al
Lycopene: features and potential significance in the oral cancer and precancerous lesions
.
J Oral Pathol Med
2011
;
40
:
361
8
.
85.
Zhang
YY
,
Lu
L
,
Abliz
G
,
Mijit
F
. 
Serum carotenoid, retinol and tocopherol concentrations and risk of cervical cancer among Chinese women
.
Asian Pacific J Cancer Prev
2015
;
16
:
2981
6
.
86.
Tang
F-Y
,
Shih
C-J
,
Cheng
L-H
,
Ho
H-J
,
Chen
H-J
. 
Lycopene inhibits growth of human colon cancer cells via suppression of the Akt signaling pathway
.
Mol Nutr Food Res
2008
;
52
:
646
54
.
87.
Assar
EA
,
Vidalle
MC
,
Chopra
M
,
Hafizi
S
. 
Lycopene acts through inhibition of IκB kinase to suppress NF-κB signaling in human prostate and breast cancer cells
.
Tumor Biol
2016
;
37
:
9375
85
.
88.
Trejo-Solís
C
,
Pedraza-Chaverrí
J
,
Torres-Ramos
M
,
Jiménez-Farfán
D
,
Cruz Salgado
A
,
Serrano-García
N
, et al
Multiple molecular and cellular mechanisms of action of lycopene in cancer inhibition
.
Evid Based Complement Alternat Med
2013
;
2013
:
705121
.
89.
Ye
M
,
Wu
Q
,
Zhang
M
,
Huang
J
. 
Lycopene inhibits the cell proliferation and invasion of human head and neck squamous cell carcinoma
.
Mol Med Rep
2016
;
14
:
2953
8
.
90.
Singh
M
,
Krishanappa
R
,
Bagewadi
A
,
Keluskar
V
. 
Efficacy of oral lycopene in the treatment of oral leukoplakia
.
Oral Oncol
2004
;
40
:
591
6
.
91.
Lodi
G
,
Sardella
A
,
Bez
C
,
Demarosi
F
,
Carrassi
A
. 
Interventions for treating oral leukoplakia
.
Cochrane Database Syst Rev
2006
:
CD001829
.
92.
Leoncini
E
,
Nedovic
D
,
Panic
N
,
Pastorino
R
,
Edefonti
V
,
Boccia
S
. 
Carotenoid intake from natural sources and head and neck cancer: a systematic review and meta-analysis of epidemiological studies
.
Cancer Epidemiol Biomark Prev
2015
;
24
:
1003
11
.
93.
Bhattacharya
S
,
Muhammad
N
,
Steele
R
,
Peng
G
,
Ray
RB
. 
Immunomodulatory role of bitter melon extract in inhibition of head and neck squamous cell carcinoma growth
.
Oncotarget
2016
;
7
:
33202
9
.
94.
Rajamoorthi
A
,
Shrivastava
S
,
Steele
R
,
Nerurkar
P
,
Gonzalez
JG
,
Crawford
S
, et al
Bitter melon reduces head and neck squamous cell carcinoma growth by targeting c-Met signaling
.
PLoS ONE
2013
;
8
:
e78006
.
95.
Bhattacharya
S
,
Muhammad
N
,
Steele
R
,
Kornbluth
J
,
Ray
RB
. 
Bitter melon enhances natural killer-mediated toxicity against head and neck cancer cells
.
Cancer Prev Res (Phila)
2017
;
10
:
337
44
.
96.
Samadi
AK
,
Tong
X
,
Mukerji
R
,
Zhang
H
,
Timmermann
BN
,
Cohen
MS
. 
Withaferin A, a cytotoxic steroid from vassobia breviflora, induces apoptosis in human head and neck squamous cell carcinoma
.
J Nat Prod
2010
;
73
:
1476
81
.
97.
Leeman-Neill
RJ
,
Wheeler
SE
,
Singh
SV
,
Thomas
SM
,
Seethala
RR
,
Neill
DB
, et al
Guggulsterone enhances head and neck cancer therapies via inhibition of signal transducer and activator of transcription-3
.
Carcinogenesis
2009
;
30
:
1848
56
.
98.
Khuri
FR
,
Lee
JJ
,
Lippman
SM
,
Kim
ES
,
Cooper
JS
,
Benner
SE
, et al
Randomized phase III trial of low-dose isotretinoin for prevention of second primary tumors in stage I and II head and neck cancer patients
.
J Nat Cancer Inst
2006
;
98
:
441
50
.
99.
Shrotriya
S
,
Agarwal
R
,
Sclafani
RA
. 
A perspective on chemoprevention by resveratrol in head and neck squamous cell carcinoma
.
Adv Exp Med Biol
2015
;
815
:
333
48
.
100.
Majumdar
D
,
Jung
KH
,
Zhang
H
,
Nannapaneni
S
,
Wang
X
,
Amin
AR
, et al
Luteolin nanoparticle in chemoprevention: in vitro and in vivo anticancer activity
.
Cancer Prev Res
2014
;
7
:
65
73
.